The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.
 
Andreas Nicholas Saltos
Honoraria - MJH Life Sciences (I)
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Zymeworks
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Genmab (Inst); Lilly (Inst); Memgen (Inst); Mersana (Inst); Novartis (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Prime Oncology
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Ben C. Creelan
Honoraria - Achilles Therapeutics; AstraZeneca; ER Squibb & Sons, LLC; Instil BIO; Roche
Speakers' Bureau - AstraZeneca; Novartis
Research Funding - Cancer Research Institute (Inst); Clinigen Group; E. R. Squibb & Sons, LLC (Inst)
Patents, Royalties, Other Intellectual Property - Patent WO2020263919A1 pending; Patent WO2021163695A2 pending
Travel, Accommodations, Expenses - AstraZeneca
 
Michael Rahman Shafique
Consulting or Advisory Role - GlaxoSmithKline; Jazz Pharmaceuticals
Research Funding - Amphivena (Inst); Daiichi Sankyo/Lilly; Merck Serono (Inst); Nektar (Inst); Pfizer (Inst); Vaccinex (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development; Nektar; Vaccinex
 
Scott Joseph Antonia
Consulting or Advisory Role - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; Celsius Therapeutics; EMD Serono; G1 Therapeutics; GlaxoSmithKline; Glympse Bio; Memgen; Merck; RAPT Therapeutics; Samyang; Tarus Therapeutics; Venn Therapeutics
Patents, Royalties, Other Intellectual Property - Oncolytic Virus
Travel, Accommodations, Expenses - Achilles Therapeutics; Amgen; Celsius Therapeutics; RAPT Therapeutics
 
Eric B. Haura
Consulting or Advisory Role - Amgen; Ellipses Pharma; Janssen; Janssen; Janssen Research & Development; Kanaph Therapeutics; ORI Capital; ORI Capital; ORI Capital; Revolution Medicines
Research Funding - AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Protein-Protein Interactions as Biomarkers Patent
 
Hong Zheng
Employment - Bristol-Myers Squibb (I)
 
Xiaoqing Yu
No Relationships to Disclose
 
James Joseph Saller
No Relationships to Disclose
 
Sebastian Viracacha
No Relationships to Disclose
 
Ram Thapa
No Relationships to Disclose
 
Theresa A. Boyle
Stock and Other Ownership Interests - Ionis Pharmaceuticals
Research Funding - Bristol Meyers Squibbs
 
Dung-Tsa Chen
No Relationships to Disclose
 
Amer A Beg
Stock and Other Ownership Interests - Alaunos Therapeutics; Cellectar
Consulting or Advisory Role - Memgen
Research Funding - Bristol-Myers Squibb/Medarex; Memgen
Patents, Royalties, Other Intellectual Property - Gene signature for the prediction of NF-kappaB activity Patent number: 9115388; IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY; ONCOLYTIC VIRUS OR ANTIGEN PRESENTING CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40-LIGAND (Pending patent)
 
Jhanelle Elaine Gray
Honoraria - Jazz Pharmaceuticals; Merck; OncoCyte
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol Myers Squibb; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Lilly; Loxo; Merck Sharp & Dohme; National Comprehensive Cancer Network; Novartis; Sanofi
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); ECOG-ACRIN (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); SWOG (Inst)
Travel, Accommodations, Expenses - Novartis; OncoCyte